Retargeting the management of hypercholesterolemia – focus on evolocumab
Alessandro Colletti,1 Giuseppe Derosa,2 Arrigo FG Cicero1 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, 2Department of Internal Medicine and Therapeutics, University of Pavia and Policlinico San Matteo Foundation, Pavia, Italy Abstract: Hypercholesterolemia is one of...
Saved in:
Main Authors: | Colletti A (Author), Derosa G (Author), Cicero AFG (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Profile of evolocumab and its potential in the treatment of hyperlipidemia
by: Cicero AF, et al.
Published: (2015) -
FDA Has Approved Evolocumab for Theatment of Familial Hypercholesterolemia in Children
by: article Editorial
Published: (2021) -
Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019) -
Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia
by: Abdulaali R. Almutairi, et al.
Published: (2024) -
Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials
by: Seyyed Majid Eslami, et al.
Published: (2017)